New chemo regimen shows promise for childhood leukemia
NCT ID NCT03165851
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study looked back at 320 children with acute myeloid leukemia (AML) who received one of two chemotherapy regimens between 2005 and 2015. The newer approach used a risk-based strategy and more intensive chemotherapy. Researchers compared survival, relapse, and remission rates to see if the newer plan worked better.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- chemotherapy (dose-dense intensive chemotherapy with high-dose cytarabine)
- What this could lead to
- If the newer regimen proves better, it could become a standard treatment for childhood AML, improving survival and remission rates.
- What could go wrong
- This is a retrospective comparison, not a randomized trial, so results may be less reliable. Chemotherapy has significant side effects, and the study does not test a new drug or cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA, PEDIATRIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
InstituteHBDH
Tianjin, Tianjin Municipality, 300020, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.